Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 4 1

Status

Recruiting 4Completed 2

Sponsor Class

OTHER 6

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 6Liver Neoplasms 2Uveal Melanoma 1Tumor Response Rate 1Neuroendocrine Tumors 1Hepatic Malignancies 1Cholangiocarcinoma 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 124Nivolumab 85pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 43Leucovorin 40tremelimumab 37camrelizumab 37Radiofrequency Ablation 37Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28cabozantinib 26Hepatectomy 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × Sirtuins × Clear all
NCT06904196 2025-04-29

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
78 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06707233 2025-01-28

Y-90 SIRT for Unresectable HCC Larger Than 7cm

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05992584 2023-09-14

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Second Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05994859 2023-09-14

SIRT for Potentially Resectable HCC

Second Affiliated Hospital of Guangzhou Medical University

Phase NA Recruiting
35 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01126645 2019-05-31

SORAMIC

University of Magdeburg

Phase 2 Completed
529 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01798160 2015-10-20

Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).

Johannes Gutenberg University Mainz

Phase 4 Completed
24 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡